We Claim:

1. A formulation suitable for oral administration comprising a therapeutically effective amount of (3,5-Bis trifluoromethyl)-N-[4-methyl-3-(4-pyridin-3yl-pyrimidin-2-yl-amino)phenyl]benzamide (NRC-AN-019) or a salt thereof, and at least one polymeric matrix agent, wherein the formulation is in the form of a solid dispersion.

2. The formulation as claimed in claim 1, wherein NRC-AN-019 is in crystalline or amorphous form or a combination thereof.

3. The formulation as claimed in claim 1 or claim 2, wherein the said NRC-AN-019 is present in an amount of 0.1% to 99.9% by weight relative to the total weight of the composition.

4. The formulation as claimed in any one of the previous claims, wherein the ratio of NRC-AN-019 to polymer matrix agent is from 1:1 to 1:8 in total weight of the composition.

5. The formulation as claimed in any one of the previous claims, wherein the polymer matrix agent is selected from an ionic polymer, a nonionic polymer and a combination thereof.

6. The formulation as claimed in claim 5, wherein the ionic polymer is selected from a cellulosic polymer, a methacrylic acid copolymer, a carboxyvinyl polymer, a vinyl acetate polymer and combinations thereof.

7. The formulation as claimed in claim 6, wherein the methacrylic acid copolymer is selected from poly(methacrylic acid, methyl methacrylate), poly(methacrylic acid, ethyl acrylate) and a combination thereof.

8. The formulation as claimed in claim 5, wherein the said non-ionic polymer is selected from a cellulosic polymer, polyvinylpyrrolidone, vinyl pyrrolidone vinyl acetate copolymer, polyalkylene glycol and combinations thereof.

9. A process for obtaining solid dispersion as claimed in claim 1, wherein the process comprises mixing NRC-AN-019 and polymeric matrix agent to form a homogeneous,

molecularly disperse mixture.

10. The process according to claim 9, wherein the process comprises a process selected from solvent controlled precipitation, solvent evaporation, lyophilisation, pH controlled precipitation, hot melt extrusion and super critical fluid technology.

11. The process according to claim 9, wherein the mixing is performed by dissolving NRC-AN-019 and polymeric matrix agent in an organic solvent, followed by spraying in to anti-solvent and obtaining co-precipitate of NRC-AN-019 and polymeric matrix agent.

12. The process according to claim 11, wherein the solvent is selected from dimethylformamide, dimethylacetamide, dimethyl sulfoxide, N-Methyl-2-pyrrolidone and mixtures thereof.

13. The process according to claim 11 wherein the anti-solvent is selected from water, hydrochloric acid, ethyl acetate, toluene, methylene chloride, acetonitrile and mixtures thereof.

14. Use of a formulation as defined in any one of claims 1 to 8 for the manufacture of a medicament for the treatment of cancer.

15. Use according to claim 14 wherein the cancer is chronic myeloid leukaemia, head cancer, neck cancer or prostate cancer.